FDA approves Ceptaris' Valchlor gel for cutaneous T-cell lymphoma

08/26/2013 | Pharmaceutical Business Review Online

The FDA has granted Ceptaris Therapeutics approval to market its Valchlor gel for treatment of patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma who previously received skin-directed treatment. The approval makes Valchlor gel the only FDA-cleared formulation of mechlorethamine, or nitrogen mustard.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations